AIMI (AIM ImmunoTech) Momentum Rank : 0 (As of Apr. 17, 2025)

View and export this data going back to 1995. Start your Free Trial

What is AIM ImmunoTech Momentum Rank?

AIM ImmunoTech has the Momentum Rank of 0.

Momentum Rank measures the strength and persistence of a stock's price movement over time, rated on a scale of 1 to 10.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

A higher score reflects strong price momentum and indicates greater potential for superior performance. Conversely, a lower score indicates that momentum is either too high or too low, and stocks tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

AIM ImmunoTech Momentum Rank Related Terms

Thank you for viewing the detailed overview of AIM ImmunoTech's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

AIM ImmunoTech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AIM ImmunoTech Inc (OTCPK:AIMI) » Definitions » Momentum Rank

Comparable Companies

Traded in Other Exchanges

0A4Y:UK HXB2:Germany

Address

2117 SW Highway 484, Ocala, FL, USA, 34473

Website

https://www.aimimmuno.com

AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

Executives

Thomas K. Equels	director, officer: Vice Chairman of Board	2117 SOUTHWEST HIGHWAY 484, OCALA FL 34473
William M Mitchell	director	2117 SW HWY 484, OCALA FL 34473
Stewart Appelrouth	director	2117 SW HIGHWAY 484, OCALA FL 34473
Rodino Peter W. Iii	director	2117 SOUTHWEST HIGHWAY 484, OCALA FL 34473
Nancy Bryan	director	550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921
Ellen M Lintal	officer: CFO	2117 SW HWY 484, OCALA FL 34473
David R Strayer	other: Medical Director	600 MAIN STREET, SUITE 2, RIVERTON NJ 08077
Wayne S. Springate	officer: VP of Operations	600 MAIN STREET, SUITE 2, RIVERTON NJ 08077
Adam Pascale	officer: CFO	600 MAIN STREET, SUITE 2, RIVERTON NJ 08077
Ralph Christopher Cavalli	officer: VP, Quality Control	510 MURDOCH ROAD, PHILADELPHIA PA 19119
Russel J Lander	officer: VP of Process/QualityAssurance	784 BAEDER ROAD, JENKINTOWN PA 19046
Robert Iv Dickey	officer: Senior Vice President	320 WEST MERMAID LANE, PHILADELPHIA PA 19118
Bernhardt Charles Thomas Iii	officer: CFO	23 BIRCH ROAD, MALVERN PA 19355
Steven D Spence	director	250 EAST 54TH STREET APARTMENT 36C, NEW YORK NY 10022
Anthony Bonelli	officer: President & COO	P.O. BOX 521, NEW VERNON NJ 07976